- Home
- CLW vs MREO Comparison
CLW vs MREO Comparison
Compare CLW & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLW | MREO |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.5M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CLW | MREO |
|---|---|---|
| Price | $17.63 | $0.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $27.00 | $3.90 |
| AVG Volume (30 Days) | 216.6K | ★ 6.1M |
| Earning Date | 02-18-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 875.72 | N/A |
| EPS | ★ 8.63 | N/A |
| Revenue | ★ $1,556,100,000.00 | $500,000.00 |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | $1.98 | ★ N/A |
| Revenue Growth | ★ 23.00 | N/A |
| 52 Week Low | $16.44 | $0.20 |
| 52 Week High | $30.96 | $3.05 |
Technical Indicators
Market Signals| Indicator | CLW | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 32.09 |
| Support Level | $16.94 | $0.36 |
| Resistance Level | $19.09 | $0.44 |
| Average True Range (ATR) | 0.78 | 0.05 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 28.63 | 17.68 |
Price Performance
Historical ComparisonAbout CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).